Myovant Sciences Competitors

Jazz Pharmaceuticals (NASDAQ:JAZZ) and Myovant Sciences (NYSE:MYOV) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, dividends, profitability, analyst recommendations, valuation, earnings and risk.

Risk and Volatility

Jazz Pharmaceuticals has a beta of 1.17, meaning that its stock price is 17% more volatile than the S&P 500. Comparatively, Myovant Sciences has a beta of 2.6, meaning that its stock price is 160% more volatile than the S&P 500.

Valuation and Earnings

This table compares Jazz Pharmaceuticals and Myovant Sciences' gross revenue, earnings per share and valuation.

Jazz Pharmaceuticals has higher revenue and earnings than Myovant Sciences. Myovant Sciences is trading at a lower price-to-earnings ratio than Jazz Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

92.8% of Jazz Pharmaceuticals shares are owned by institutional investors. Comparatively, 35.6% of Myovant Sciences shares are owned by institutional investors. 4.6% of Jazz Pharmaceuticals shares are owned by company insiders. Comparatively, 3.9% of Myovant Sciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of current recommendations for Jazz Pharmaceuticals and Myovant Sciences, as reported by MarketBeat.

Jazz Pharmaceuticals presently has a consensus target price of $172.1176, indicating a potential upside of 21.35%. Myovant Sciences has a consensus target price of $32.25, indicating a potential upside of 47.60%. Given Myovant Sciences' higher probable upside, analysts plainly believe Myovant Sciences is more favorable than Jazz Pharmaceuticals.

Profitability

This table compares Jazz Pharmaceuticals and Myovant Sciences' net margins, return on equity and return on assets.

Summary

Jazz Pharmaceuticals beats Myovant Sciences on 11 of the 13 factors compared between the two stocks.

Galapagos (NASDAQ:GLPG) and Myovant Sciences (NYSE:MYOV) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, dividends, profitability, analyst recommendations, valuation, earnings and risk.

Valuation and Earnings

This table compares Galapagos and Myovant Sciences' gross revenue, earnings per share and valuation.

Galapagos has higher revenue and earnings than Myovant Sciences. Myovant Sciences is trading at a lower price-to-earnings ratio than Galapagos, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Galapagos has a beta of 0.79, meaning that its stock price is 21% less volatile than the S&P 500. Comparatively, Myovant Sciences has a beta of 2.6, meaning that its stock price is 160% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current recommendations for Galapagos and Myovant Sciences, as reported by MarketBeat.

Galapagos presently has a consensus target price of $180.1538, indicating a potential upside of 49.16%. Myovant Sciences has a consensus target price of $32.25, indicating a potential upside of 47.60%. Given Galapagos' higher probable upside, research analysts plainly believe Galapagos is more favorable than Myovant Sciences.

Profitability

This table compares Galapagos and Myovant Sciences' net margins, return on equity and return on assets.

Insider and Institutional Ownership

11.6% of Galapagos shares are owned by institutional investors. Comparatively, 35.6% of Myovant Sciences shares are owned by institutional investors. 2.9% of Galapagos shares are owned by company insiders. Comparatively, 3.9% of Myovant Sciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Summary

Galapagos beats Myovant Sciences on 7 of the 12 factors compared between the two stocks.

Myovant Sciences (NYSE:MYOV) and Ultragenyx Pharmaceutical (NASDAQ:RARE) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, valuation, analyst recommendations, profitability, dividends, institutional ownership and risk.

Earnings and Valuation

This table compares Myovant Sciences and Ultragenyx Pharmaceutical's gross revenue, earnings per share (EPS) and valuation.

Myovant Sciences has higher earnings, but lower revenue than Ultragenyx Pharmaceutical. Ultragenyx Pharmaceutical is trading at a lower price-to-earnings ratio than Myovant Sciences, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Myovant Sciences has a beta of 2.6, indicating that its share price is 160% more volatile than the S&P 500. Comparatively, Ultragenyx Pharmaceutical has a beta of 2.18, indicating that its share price is 118% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings for Myovant Sciences and Ultragenyx Pharmaceutical, as reported by MarketBeat.com.

Myovant Sciences presently has a consensus price target of $32.25, indicating a potential upside of 47.60%. Ultragenyx Pharmaceutical has a consensus price target of $94.7059, indicating a potential downside of 20.97%. Given Myovant Sciences' stronger consensus rating and higher probable upside, equities research analysts plainly believe Myovant Sciences is more favorable than Ultragenyx Pharmaceutical.

Profitability

This table compares Myovant Sciences and Ultragenyx Pharmaceutical's net margins, return on equity and return on assets.

Insider and Institutional Ownership

35.6% of Myovant Sciences shares are owned by institutional investors. 3.9% of Myovant Sciences shares are owned by insiders. Comparatively, 8.2% of Ultragenyx Pharmaceutical shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Myovant Sciences beats Ultragenyx Pharmaceutical on 9 of the 13 factors compared between the two stocks.

Myovant Sciences (NYSE:MYOV) and Ionis Pharmaceuticals (NASDAQ:IONS) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, valuation, analyst recommendations, profitability, dividends, institutional ownership and risk.

Earnings and Valuation

This table compares Myovant Sciences and Ionis Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Ionis Pharmaceuticals has higher revenue and earnings than Myovant Sciences. Myovant Sciences is trading at a lower price-to-earnings ratio than Ionis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Myovant Sciences has a beta of 2.6, indicating that its share price is 160% more volatile than the S&P 500. Comparatively, Ionis Pharmaceuticals has a beta of 1.44, indicating that its share price is 44% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings for Myovant Sciences and Ionis Pharmaceuticals, as reported by MarketBeat.com.

Myovant Sciences presently has a consensus price target of $32.25, indicating a potential upside of 47.60%. Ionis Pharmaceuticals has a consensus price target of $68.1818, indicating a potential upside of 35.71%. Given Myovant Sciences' stronger consensus rating and higher probable upside, equities research analysts plainly believe Myovant Sciences is more favorable than Ionis Pharmaceuticals.

Profitability

This table compares Myovant Sciences and Ionis Pharmaceuticals' net margins, return on equity and return on assets.

Insider and Institutional Ownership

35.6% of Myovant Sciences shares are owned by institutional investors. Comparatively, 85.4% of Ionis Pharmaceuticals shares are owned by institutional investors. 3.9% of Myovant Sciences shares are owned by insiders. Comparatively, 2.4% of Ionis Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Ionis Pharmaceuticals beats Myovant Sciences on 9 of the 13 factors compared between the two stocks.

Myovant Sciences (NYSE:MYOV) and Bausch Health Companies (NYSE:BHC) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, valuation, analyst recommendations, profitability, dividends, institutional ownership and risk.

Earnings and Valuation

This table compares Myovant Sciences and Bausch Health Companies' gross revenue, earnings per share (EPS) and valuation.

Myovant Sciences has higher earnings, but lower revenue than Bausch Health Companies. Myovant Sciences is trading at a lower price-to-earnings ratio than Bausch Health Companies, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Myovant Sciences has a beta of 2.6, indicating that its share price is 160% more volatile than the S&P 500. Comparatively, Bausch Health Companies has a beta of 1.42, indicating that its share price is 42% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings for Myovant Sciences and Bausch Health Companies, as reported by MarketBeat.com.

Myovant Sciences presently has a consensus price target of $32.25, indicating a potential upside of 47.60%. Bausch Health Companies has a consensus price target of $29.75, indicating a potential upside of 55.19%. Given Bausch Health Companies' higher probable upside, analysts plainly believe Bausch Health Companies is more favorable than Myovant Sciences.

Profitability

This table compares Myovant Sciences and Bausch Health Companies' net margins, return on equity and return on assets.

Insider and Institutional Ownership

35.6% of Myovant Sciences shares are owned by institutional investors. Comparatively, 62.2% of Bausch Health Companies shares are owned by institutional investors. 3.9% of Myovant Sciences shares are owned by insiders. Comparatively, 12.1% of Bausch Health Companies shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Bausch Health Companies beats Myovant Sciences on 9 of the 13 factors compared between the two stocks.

Myovant Sciences (NYSE:MYOV) and Perrigo (NYSE:PRGO) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, valuation, analyst recommendations, profitability, dividends, institutional ownership and risk.

Earnings and Valuation

This table compares Myovant Sciences and Perrigo's gross revenue, earnings per share (EPS) and valuation.

Perrigo has higher revenue and earnings than Myovant Sciences. Myovant Sciences is trading at a lower price-to-earnings ratio than Perrigo, indicating that it is currently the more affordable of the two stocks.

Risk & Volatility

Myovant Sciences has a beta of 2.6, indicating that its share price is 160% more volatile than the S&P 500. Comparatively, Perrigo has a beta of 1.15, indicating that its share price is 15% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings for Myovant Sciences and Perrigo, as reported by MarketBeat.com.

Myovant Sciences presently has a consensus price target of $32.25, indicating a potential upside of 47.60%. Perrigo has a consensus price target of $58.3333, indicating a potential upside of 21.71%. Given Myovant Sciences' stronger consensus rating and higher probable upside, equities research analysts plainly believe Myovant Sciences is more favorable than Perrigo.

Profitability

This table compares Myovant Sciences and Perrigo's net margins, return on equity and return on assets.

Insider and Institutional Ownership

35.6% of Myovant Sciences shares are owned by institutional investors. Comparatively, 83.5% of Perrigo shares are owned by institutional investors. 3.9% of Myovant Sciences shares are owned by insiders. Comparatively, 0.3% of Perrigo shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Perrigo beats Myovant Sciences on 8 of the 12 factors compared between the two stocks.